Pharmaceutical company Tryp Therapeutics Inc. (CNSX: TRYP) has appointed Greg McKee as its new Chief Executive Officer. Following this appointment, MCKee will double up as the CEO and Chairman of the Board of Directors at the company.
The new chief executive assumes office with a massive experience in leading public traded pharmaceutical companies, he also bears the much needed knowledge and networks in the life sciences industry to move Tryp to a next level.
MCKee kicked off his career at Genzyme where he was in charge of commercializing leading compounds for rare diseases across Asia. Thereafter he served as Chairman and CEO in Akela Pharma and Nventa Biopharmaceuticals Corp.
Mr. MCKee was appointed as Chairman of the Board of Directors of Tryp in February this year. The managing director of Tryp William Garner said MCKnee has performed tremendously well in his position in the company’s board and that he was the best suited to take the company to the next growth phase.
“Greg has provided exceptional vision and leadership to Tryp since his appointment as Chairman of the Board, and he is ideally suited to lead the Company’s next phase of growth. We are fortunate to have him serve the company in this expanded capacity as Chief Executive Officer,” said Warner.